FDA Accepts sBLA for Daratumumab, Hyaluronidase-fihj for Treatment of Multiple Myeloma

by | Feb 2, 2024 | Myeloma News | 0 comments

Source: Pharmacy Times articles

Daratumumab and hyaluronidase-fihj in combination with other therapies was previously approved by the FDA in May 2020 for 8 indications in multiple myeloma.
Read More

Submit a Comment